News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
GlaxoSmithKline’s Pazopanib Shows Promise in Ovarian Cancer
September 15, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Sept 15 (Reuters) - GlaxoSmithKline's experimental drug pazopanib appears to be effective in fighting ovarian cancer, based on measurements of a biological marker used to predict tumour recurrence, researchers said on Monday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
GlaxoSmithKline
MORE ON THIS TOPIC
GLP-1
Lilly’s Oral GLP-1 Bests Another Big Pharma Bestseller in Phase III Diabetes Trial
October 15, 2025
·
2 min read
·
Annalee Armstrong
Podcast
Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC
October 15, 2025
·
1 min read
·
Heather McKenzie
Gene therapy
Regeneron Readies FDA Run for Hearing Loss Gene Therapy That Could ‘Transform Patients’ Lives’
October 13, 2025
·
2 min read
·
Tristan Manalac
Cancer
Moderna Claims Early Victory for Cancer Antigen in Melanoma
October 13, 2025
·
2 min read
·
Tristan Manalac
